Selected publications:

Click on the title to go to PubMed

• Access to biologicals in Crohn’s disease in ten European countries.

• Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. 

• The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

• Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.

• Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists

• Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.in reimbursement decisions in three European countries.

• Preferences of Hungarian consumers for quality, access and price attributes of health care services.

• Quality management and patient safety: survey results from 102 Hungarian hospitals